Secorapamycin A
CAS: 147438-27-5
Ref. 3D-XFA43827
1mg | A consultar | ||
5mg | A consultar | ||
10mg | A consultar | ||
25mg | A consultar | ||
50mg | A consultar |
Información del producto
- 2-Piperidinecarboxylicacid, 1-[oxo[(2R,3R,6S)-tetrahydro-2-hydroxy-6-[(2S,3E,5E,7E,9S,11R,13R,14R,15E,17R,19E,21R)-14-hydroxy-22-[(1S,3R,4R)-4-hydroxy-3-methoxycyclohexyl]-2,13-dimethoxy-3,9,11,15,17,21-hexamethyl-12,18-dioxo-3,5,7,15,19-docosapentaenyl]-3-methyl-2H-pyran-2-yl]acetyl]-(9CI)
- 2-Piperidinecarboxylic acid,1-[oxo[tetrahydro-2-hydroxy-6-[14-hydroxy-22-(4-hydroxy-3-methoxycyclohexyl)-2,13-dimethoxy-3,9,11,15,17,21-hexamethyl-12,18-dioxo-3,5,7,15,19-docosapentaenyl]-3-methyl-2H-pyran-2-yl]acetyl]-,[2R-[2a,2(S*),3a,6b[2S*,3E,5E,7E,9S*,11R*,13R*,14R*,15E,17R*,19E,21R*,22(1S*,3R*,4R*)]]]-
Secorapamycin A is a small molecule activator of the protein tyrosine phosphatase-1b (PTP-1B). Secorapamycin A binds to PTP-1B and increases its activity, resulting in inhibition of the nuclear factor kappa B (NF-κB) pathway. Secorapamycin A has been shown to inhibit ion channels, such as potassium channels, and to bind to antibodies. This drug also binds to receptors, including ligand binding domain on the human epidermal growth factor receptor 2 (HER2), which is expressed in some breast cancer cells. Secorapamycin A has also been found to inhibit cell proliferation by inhibiting protein synthesis.
Propiedades químicas
Consulta técnica sobre: 3D-XFA43827 Secorapamycin A
Si desea solicitar un presupuesto o realizar un pedido, por favor añada los productos deseados a su carrito y solicite un presupuesto o pedido desde el carrito. Es más rápido, más barato, y podrá beneficiarse de los descuentos y las ventajas disponibles.